Latest Breaking News On - Access consortium new active substance initiative - Page 1 : comparemela.com

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSouth koreaGreat britainMaryline ivaKyle blankenshipLiza heapesMehrdad mobasherLuigi zinzaniEuropean unionUniversity of bolognaInstitute of haematology serBeigene ltdEuropean commissionAccess consortium new active substance initiativeExchange commission

BeiGene (BGNE) Announces EU Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene (BGNE) Announces EU Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesUnited kingdomGreat britainLuigi zinzaniMehrdad mobasherInstitute of haematology serBeigene ltdAccess consortium new active substance initiativeUniversity of bolognaEuropean unionEuropean commissionChief medical officerPier luigi zinzaniFull professorSenior vice president

BeiGene, Ltd : BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd : BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomRheinland pfalzUnited statesSouth koreaGreat britainLiza heapesKyle blankenshipMehrdad mobasherLuigi zinzaniMaryline ivaAccess consortium new active substance initiativeEuropean commissionWorld health organizationAmerican cancer societyBeigene ltdEuropean union

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., October 13, 2023 BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of BRUKINSA® (zanubrutinib), a Bruton’s tyrosine kinase inhibitor (BTKi), in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicul

South koreaUnited statesUnited kingdomGreat britainMehrdad mobasherLiza heapesMaryline ivaKyle blankenshipEuropean commissionEuropean unionAccess consortium new active substance initiativeAmerican cancer societyWorld health organizationLeukemia lymphoma societyEuropean medicines agencyCommittee for medicinal products human use

BeiGene (BGNE) Receives Positive CHMP Opinion for BRUKINSA in Relapsed or Refractory Follicular Lymphoma

BeiGene (BGNE) Receives Positive CHMP Opinion for BRUKINSA in Relapsed or Refractory Follicular Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited kingdomUnited statesGreat britainMehrdad mobasherEuropean unionEuropean commissionCommittee for medicinal products human useEuropean medicines agencyAccess consortium new active substance initiativeMedicinal productsHuman useChief medical officerMarketing application